CAP-100 drug study for hard-to-treat CLL after prior treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase (Phase 1) study tests CAP-100 in adults with CLL or SLL that has come back or did not respond to at least two previous treatments. The goal is to see how the drug works and whether it is safe enough to keep studying.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent papers.
- Your CLL/SLL should be “relapsed” or “refractory” after at least two prior standard treatment types, and no other known treatment should be expected to help.
- You must have stopped prior CLL/SLL medicines long enough before starting CAP-100 (with limited allowance for bridging low-dose steroids).
- Your general health must be good enough (ECOG 0–2), and you should be expected to live more than 16 weeks.
- Your blood, liver, and kidney tests must meet minimum levels (including platelets, liver enzymes, and kidney function).
- You must not have certain recent treatments or conditions (like a recent transplant, recent monoclonal antibody therapy, active serious infection, or active CNS lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
This Phase 2 study compares a “point-of-care” CAR T-cell treatment made at the hospital right away versus standard commercial CAR T-cells. It’s for adults with relapsed or refractory large B-cell lymphoma (a type of blood cancer) to see which approach works best and is safe.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
Hear when a new SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.